vs
Federal Realty Investment Trust（FRT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Federal Realty Investment Trust的1.9倍（$622.0M vs $336.0M），Federal Realty Investment Trust净利率更高（38.6% vs 34.4%，领先4.2%），Federal Realty Investment Trust同比增速更快（8.7% vs 4.8%），过去两年Federal Realty Investment Trust的营收复合增速更高（6.5% vs 4.6%）
Federal Realty Investment Trust是一家专业房地产投资信托基金，核心投资标的为购物中心类商业物业，资产布局覆盖美国东北部、大西洋中部地区、加利福尼亚州及南佛罗里达区域，在当地商业不动产投资领域拥有丰富的运营经验。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FRT vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.9倍
$336.0M
营收增速更快
FRT
高出3.9%
4.8%
净利率更高
FRT
高出4.2%
34.4%
两年增速更快
FRT
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $336.0M | $622.0M |
| 净利润 | $129.7M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 53.8% | 62.4% |
| 净利率 | 38.6% | 34.4% |
| 营收同比 | 8.7% | 4.8% |
| 净利润同比 | 103.5% | 2.9% |
| 每股收益（稀释后） | $1.49 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRTRPRX
| Q1 26 | $336.0M | — | ||
| Q4 25 | $336.0M | $622.0M | ||
| Q3 25 | $322.3M | $609.3M | ||
| Q2 25 | $311.5M | $578.7M | ||
| Q1 25 | $309.2M | $568.2M | ||
| Q4 24 | $311.4M | $593.6M | ||
| Q3 24 | $303.6M | $564.7M | ||
| Q2 24 | $296.1M | $537.3M |
净利润FRTRPRX
| Q1 26 | $129.7M | — | ||
| Q4 25 | $129.7M | $214.2M | ||
| Q3 25 | $61.6M | $288.2M | ||
| Q2 25 | $155.9M | $30.2M | ||
| Q1 25 | $63.8M | $238.3M | ||
| Q4 24 | $65.5M | $208.2M | ||
| Q3 24 | $61.0M | $544.0M | ||
| Q2 24 | $112.0M | $102.0M |
营业利润率FRTRPRX
| Q1 26 | 53.8% | — | ||
| Q4 25 | 53.8% | 62.4% | ||
| Q3 25 | 34.3% | 70.1% | ||
| Q2 25 | 65.1% | 36.3% | ||
| Q1 25 | 35.0% | 94.0% | ||
| Q4 24 | 35.1% | 60.9% | ||
| Q3 24 | 34.9% | — | ||
| Q2 24 | 53.0% | 50.2% |
净利率FRTRPRX
| Q1 26 | 38.6% | — | ||
| Q4 25 | 38.6% | 34.4% | ||
| Q3 25 | 19.1% | 47.3% | ||
| Q2 25 | 50.0% | 5.2% | ||
| Q1 25 | 20.6% | 41.9% | ||
| Q4 24 | 21.0% | 35.1% | ||
| Q3 24 | 20.1% | 96.3% | ||
| Q2 24 | 37.8% | 19.0% |
每股收益（稀释后）FRTRPRX
| Q1 26 | $1.49 | — | ||
| Q4 25 | $1.49 | $0.49 | ||
| Q3 25 | $0.69 | $0.67 | ||
| Q2 25 | $1.78 | $0.07 | ||
| Q1 25 | $0.72 | $0.55 | ||
| Q4 24 | $0.74 | $0.46 | ||
| Q3 24 | $0.70 | $1.21 | ||
| Q2 24 | $1.32 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $107.4M | $618.7M |
| 总债务越低越好 | $5.0B | $9.0B |
| 股东权益账面价值 | $3.2B | $9.7B |
| 总资产 | $9.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.53× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FRTRPRX
| Q1 26 | $107.4M | — | ||
| Q4 25 | $107.4M | $618.7M | ||
| Q3 25 | $111.3M | $938.9M | ||
| Q2 25 | $177.0M | $631.9M | ||
| Q1 25 | $109.2M | $1.1B | ||
| Q4 24 | $123.4M | $929.0M | ||
| Q3 24 | $97.0M | $950.1M | ||
| Q2 24 | $103.2M | $1.8B |
总债务FRTRPRX
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $4.5B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益FRTRPRX
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $9.7B | ||
| Q3 25 | $3.2B | $9.6B | ||
| Q2 25 | $3.2B | $9.5B | ||
| Q1 25 | $3.2B | $9.8B | ||
| Q4 24 | $3.2B | $10.3B | ||
| Q3 24 | $3.1B | $10.3B | ||
| Q2 24 | $3.0B | $9.8B |
总资产FRTRPRX
| Q1 26 | $9.1B | — | ||
| Q4 25 | $9.1B | $19.6B | ||
| Q3 25 | $8.9B | $19.3B | ||
| Q2 25 | $8.6B | $18.3B | ||
| Q1 25 | $8.6B | $17.6B | ||
| Q4 24 | $8.5B | $18.2B | ||
| Q3 24 | $8.5B | $18.0B | ||
| Q2 24 | $8.4B | $17.7B |
负债/权益比FRTRPRX
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.53× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.42× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FRTRPRX
| Q1 26 | — | — | ||
| Q4 25 | $622.4M | $827.1M | ||
| Q3 25 | $147.8M | $702.6M | ||
| Q2 25 | $150.7M | $364.0M | ||
| Q1 25 | $179.0M | $596.1M | ||
| Q4 24 | $574.6M | $742.5M | ||
| Q3 24 | $144.1M | $703.6M | ||
| Q2 24 | $169.7M | $658.2M |
现金转化率FRTRPRX
| Q1 26 | — | — | ||
| Q4 25 | 4.80× | 3.86× | ||
| Q3 25 | 2.40× | 2.44× | ||
| Q2 25 | 0.97× | 12.06× | ||
| Q1 25 | 2.81× | 2.50× | ||
| Q4 24 | 8.77× | 3.57× | ||
| Q3 24 | 2.36× | 1.29× | ||
| Q2 24 | 1.52× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRT
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
